These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 29986966)

  • 41. DAPT Plus Cilostazol is Better Than Traditional DAPT or Aspirin Plus Ticagrelor as Elective PCI for Intermediate-to-Highly Complex Cases: Prospective, Randomized, PRU-Based Study in Taiwan.
    Chen YC; Lin FY; Lin YW; Cheng SM; Lin RH; Chuang CL; Sheu JS; Chen SM; Chang CC; Tsai CS
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):75-86. PubMed ID: 30467686
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of TIcagrelor administered through a nasogastric tube to COMAtose patients undergoing acute percutaneous coronary intervention: the TICOMA study.
    Ratcovich H; Sadjadieh G; Andersson HB; Frydland M; Wiberg S; Dridi NP; Kjaergaard J; Holmvang L
    EuroIntervention; 2017 Feb; 12(14):1782-1788. PubMed ID: 28216475
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ticagrelor Versus Clopidogrel in Comatose Survivors of Out-of-Hospital Cardiac Arrest Undergoing Percutaneous Coronary Intervention and Hypothermia: A Randomized Study.
    Steblovnik K; Blinc A; Mijovski MB; Fister M; Mikuz U; Noc M
    Circulation; 2016 Dec; 134(25):2128-2130. PubMed ID: 27994027
    [No Abstract]   [Full Text] [Related]  

  • 44. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study.
    Parodi G; Valenti R; Bellandi B; Migliorini A; Marcucci R; Comito V; Carrabba N; Santini A; Gensini GF; Abbate R; Antoniucci D
    J Am Coll Cardiol; 2013 Apr; 61(15):1601-6. PubMed ID: 23500251
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Midterm follow-up outcomes of ticagrelor on acute ST segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention].
    Xia JG; Qu Y; Hu SD; Xu J; Yin CL; Xu D
    Beijing Da Xue Xue Bao Yi Xue Ban; 2015 Jun; 47(3):494-8. PubMed ID: 26080882
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
    Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
    JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of ticagrelor versus prasugrel on platelet reactivity: a meta-analysis.
    Zhang H; Zhang P; Dong P; Yang X; Wang Y; Zhang H; Yan J; Zhang Y; Zhang T; Li Y
    Coron Artery Dis; 2017 Nov; 28(7):597-604. PubMed ID: 28968313
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential effect of ticagrelor versus prasugrel on coronary blood flow velocity in patients with non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: an exploratory study.
    Alexopoulos D; Moulias A; Koutsogiannis N; Xanthopoulou I; Kakkavas A; Mavronasiou E; Davlouros P; Hahalis G
    Circ Cardiovasc Interv; 2013 Jun; 6(3):277-83. PubMed ID: 23735473
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chewing versus Swallowing Ticagrelor to Accelerate Platelet Inhibition in Acute Coronary Syndrome - the CHEERS study. For The PLATIS (Platelets and Thrombosis in Sheba) Study Group.
    Asher E; Frydman S; Katz M; Regev E; Sabbag A; Mazin I; Abu-Much A; Kukuy A; Mazo A; Erez A; Berkovitch A; Narodistky M; Barbash I; Segev A; Beigel R; Matetzky S
    Thromb Haemost; 2017 Apr; 117(4):727-733. PubMed ID: 28150850
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI.
    Yang A; Pon Q; Lavoie A; Crawford JJ; Harenberg S; Zimmermann RH; Booker J; Kelly S; Lavi S; Cantor WJ; Mehta SR; Bagai A; Goodman SG; Cheema AN; Dehghani P
    J Thromb Thrombolysis; 2018 Feb; 45(2):225-233. PubMed ID: 29170875
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of adenosine A2a receptor polymorphism rs5751876 on platelet reactivity in ticagrelor treated patients.
    Nardin M; Verdoia M; Pergolini P; Rolla R; Barbieri L; Marino P; Bellomo G; Kedhi E; Suryapranata H; Carriero A; De Luca G;
    Pharmacol Res; 2018 Mar; 129():27-33. PubMed ID: 29355684
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention.
    Laine M; Toesca R; Berbis J; Frere C; Barnay P; Pansieri M; Peyre JP; Michelet P; Bessereau J; Camilleri E; Helaf O; Camaleonte M; Paganelli F; Dignat-George F; Bonello L
    Thromb Res; 2013 Jul; 132(1):e15-8. PubMed ID: 23726090
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational study.
    Alexopoulos D; Vogiatzi C; Stavrou K; Vlassopoulou N; Perperis A; Pentara I; Xanthopoulou I
    Cardiovasc Diabetol; 2015 May; 14():68. PubMed ID: 26025572
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor.
    Nardin M; Verdoia M; Sartori C; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
    J Cardiovasc Pharmacol; 2015 Oct; 66(4):364-70. PubMed ID: 26065844
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G
    Expert Opin Pharmacother; 2015; 16(12):1739-47. PubMed ID: 26067422
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of a 180 mg ticagrelor loading dose on myocardial necrosis in patients undergoing elective percutaneous coronary intervention: A preliminary study.
    Xu Q; Sun Y; Zhang Y; Liu B; Fang L; Shen C; Li Y; Meng S
    Cardiol J; 2017; 24(1):15-24. PubMed ID: 28070882
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
    Parodi G; Bellandi B; Valenti R; Migliorini A; Marcucci R; Carrabba N; Giurlani L; Gensini GF; Abbate R; Antoniucci D
    Am Heart J; 2014 Jun; 167(6):909-14. PubMed ID: 24890542
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
    Husted S; James S; Becker RC; Horrow J; Katus H; Storey RF; Cannon CP; Heras M; Lopes RD; Morais J; Mahaffey KW; Bach RG; Wojdyla D; Wallentin L;
    Circ Cardiovasc Qual Outcomes; 2012 Sep; 5(5):680-8. PubMed ID: 22991347
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study.
    Laine M; Frère C; Toesca R; Berbis J; Barnay P; Pansieri M; Michelet P; Bessereau J; Camilleri E; Ronsin O; Helal O; Paganelli F; Dignat-George F; Bonello L
    Thromb Haemost; 2014 Feb; 111(2):273-8. PubMed ID: 24154787
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improved ticagrelor antiplatelet effect on discontinuation of phenytoin.
    Weeks P; Sieg A; Vahdat K; Raissi F; Nathan S
    Ann Pharmacother; 2014 May; 48(5):644-7. PubMed ID: 24477376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.